Lyell Immunopharma Inc (NASDAQ:LYEL) has a beta value of -0.48 and has seen 1.01 million shares traded in the last trading session. The company, currently valued at $274.93M, closed the last trade at $0.95 per share which meant it gained $0.03 on the day or 3.64% during that session. The LYEL stock price is -243.16% off its 52-week high price of $3.26 and 10.53% above the 52-week low of $0.85. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.38 million shares traded. The 3-month trading volume is 1.19 million shares.

The consensus among analysts is that Lyell Immunopharma Inc (LYEL) is Hold stock at the moment, with a recommendation rating of 3.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 3 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.

Lyell Immunopharma Inc (NASDAQ:LYEL) trade information

Sporting 3.64% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the LYEL stock price touched $0.95 or saw a rise of 18.1%. Year-to-date, Lyell Immunopharma Inc shares have moved -51.03%, while the 5-day performance has seen it change -13.64%. Over the past 30 days, the shares of Lyell Immunopharma Inc (NASDAQ:LYEL) have changed -12.84%. Short interest in the company has seen 11.14 million shares shorted with days to cover at 7.69.

Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could jump 86.43% from current levels. The projected low price target is $1.0 while the price target rests at a high of $12.0. In that case, then, we find that the current price level is -1163.16% off the targeted high while a plunge would see the stock gain -5.26% from current levels.

Lyell Immunopharma Inc (LYEL) estimates and forecasts

Figures show that Lyell Immunopharma Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -65.70% over the past 6 months, with this year growth rate of 13.98%, compared to 16.70% for the industry. Revenue growth from the last financial year stood is estimated to be -74.62%.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -15.28% over the past 5 years. Earnings growth for 2024 is a modest 14.52% while over the next 5 years, the company’s earnings are expected to decrease by -7.90%.

LYEL Dividends

Lyell Immunopharma Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders

Insiders own 14.06% of the company shares, while shares held by institutions stand at 61.65% with a share float percentage of 71.73%. Investors are also buoyed by the number of investors in a company, with Lyell Immunopharma Inc having a total of 167.0 institutions that hold shares in the company. The top two institutional holders are MWG MANAGEMENT LTD. with over 20.16 million shares worth more than $29.24 million. As of 2024-06-30, MWG MANAGEMENT LTD. held 7.9301% of shares outstanding.

The other major institutional holder is ORLAND PROPERTIES LTD, with the holding of over 15.09 million shares as of 2024-06-30. The firm’s total holdings are worth over $21.89 million and represent 5.9366% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Price (T.Rowe) Health Sciences Fund and Vanguard Total Stock Market Index Fund . As of Jun 30, 2024 , the former fund manager holds about 2.12% shares in the company for having 5.92 shares of worth $5.63 million while later fund manager owns 5.82 shares of worth $5.53 million as of Jun 30, 2024 , which makes it owner of about 2.08% of company’s outstanding stock.